Corline Biomedical AB
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting. Its products … Read more
Corline Biomedical AB (CLBIO) - Net Assets
Latest net assets as of September 2025: Skr77.23 Million SEK
Based on the latest financial reports, Corline Biomedical AB (CLBIO) has net assets worth Skr77.23 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr82.31 Million) and total liabilities (Skr5.09 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr77.23 Million |
| % of Total Assets | 93.82% |
| Annual Growth Rate | 41.3% |
| 5-Year Change | 67.04% |
| 10-Year Change | 309.0% |
| Growth Volatility | 146.88 |
Corline Biomedical AB - Net Assets Trend (2012–2024)
This chart illustrates how Corline Biomedical AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Corline Biomedical AB (2012–2024)
The table below shows the annual net assets of Corline Biomedical AB from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr86.91 Million | -6.86% |
| 2023-12-31 | Skr93.32 Million | -1.35% |
| 2022-12-31 | Skr94.59 Million | +2.55% |
| 2021-12-31 | Skr92.23 Million | +77.26% |
| 2020-12-31 | Skr52.03 Million | -12.28% |
| 2019-12-31 | Skr59.32 Million | +7.93% |
| 2018-12-31 | Skr54.96 Million | +19.68% |
| 2017-12-31 | Skr45.93 Million | +18.53% |
| 2016-12-31 | Skr38.75 Million | +82.33% |
| 2015-12-31 | Skr21.25 Million | +287.44% |
| 2014-12-31 | Skr5.48 Million | -31.41% |
| 2013-12-31 | Skr8.00 Million | +482.77% |
| 2012-12-31 | Skr1.37 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Corline Biomedical AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13691840200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr3.06 Million | 3.52% |
| Other Comprehensive Income | Skr60.58 Million | 69.71% |
| Other Components | Skr171.39 Million | 197.19% |
| Total Equity | Skr86.91 Million | 100.00% |
Corline Biomedical AB Competitors by Market Cap
The table below lists competitors of Corline Biomedical AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SILVER DOLLAR RES
F:4YW
|
$10.85 Million |
|
Nasus Pharma Ltd.
NYSE MKT:NSRX
|
$10.85 Million |
|
Secova Metals Corp
OTCQB:SEKZF
|
$10.85 Million |
|
Eyesvision Corp
KQ:031310
|
$10.85 Million |
|
Silverline Endustri ve Ticaret AS
IS:SILVR
|
$10.85 Million |
|
TRANSDIGM
BE:T7D
|
$10.84 Million |
|
Konsortium Transnasional Bhd
KLSE:4847
|
$10.84 Million |
|
Two Hands Corp
PINK:TWOH
|
$10.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Corline Biomedical AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 93,316,000 to 86,914,000, a change of -6,402,000 (-6.9%).
- Net loss of 23,194,000 reduced equity.
- Share repurchases of 18,224,000 reduced equity.
- New share issuances of 16,792,000 increased equity.
- Other comprehensive income decreased equity by 2,495,000.
- Other factors increased equity by 20,719,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-23.19 Million | -26.69% |
| Share Repurchases | Skr18.22 Million | -20.97% |
| Share Issuances | Skr16.79 Million | +19.32% |
| Other Comprehensive Income | Skr-2.50 Million | -2.87% |
| Other Changes | Skr20.72 Million | +23.84% |
| Total Change | Skr- | -6.86% |
Book Value vs Market Value Analysis
This analysis compares Corline Biomedical AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.79x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 256.51x to 3.79x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | Skr0.06 | Skr15.10 | x |
| 2013-12-31 | Skr0.81 | Skr15.10 | x |
| 2014-12-31 | Skr0.55 | Skr15.10 | x |
| 2015-12-31 | Skr2.41 | Skr15.10 | x |
| 2016-12-31 | Skr3.20 | Skr15.10 | x |
| 2017-12-31 | Skr3.37 | Skr15.10 | x |
| 2018-12-31 | Skr3.53 | Skr15.10 | x |
| 2019-12-31 | Skr3.54 | Skr15.10 | x |
| 2020-12-31 | Skr3.03 | Skr15.10 | x |
| 2021-12-31 | Skr4.51 | Skr15.10 | x |
| 2022-12-31 | Skr4.40 | Skr15.10 | x |
| 2023-12-31 | Skr4.30 | Skr15.10 | x |
| 2024-12-31 | Skr3.98 | Skr15.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Corline Biomedical AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -26.69%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -237.28%
- • Asset Turnover: 0.10x
- • Equity Multiplier: 1.09x
- Recent ROE (-26.69%) is above the historical average (-28.23%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -155.88% | -15.19% | 0.48x | 21.31x | Skr-969.94K |
| 2013 | -31.11% | -139.17% | 0.13x | 1.72x | Skr-3.29 Million |
| 2014 | -45.80% | -149.25% | 0.10x | 3.06x | Skr-3.06 Million |
| 2015 | -27.51% | -563.62% | 0.04x | 1.18x | Skr-7.97 Million |
| 2016 | -13.54% | -554.17% | 0.02x | 1.07x | Skr-9.12 Million |
| 2017 | -17.01% | -1224.14% | 0.01x | 1.12x | Skr-12.40 Million |
| 2018 | -12.36% | -434.61% | 0.02x | 1.14x | Skr-12.29 Million |
| 2019 | -16.08% | -896.62% | 0.02x | 1.07x | Skr-15.47 Million |
| 2020 | -14.00% | -197.16% | 0.06x | 1.12x | Skr-12.49 Million |
| 2021 | -7.50% | -97.93% | 0.07x | 1.10x | Skr-16.14 Million |
| 2022 | 2.46% | 9.89% | 0.23x | 1.08x | Skr-7.13 Million |
| 2023 | -1.94% | -7.23% | 0.25x | 1.07x | Skr-11.14 Million |
| 2024 | -26.69% | -237.28% | 0.10x | 1.09x | Skr-31.89 Million |
Industry Comparison
This section compares Corline Biomedical AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Corline Biomedical AB (CLBIO) | Skr77.23 Million | -155.88% | 0.07x | $10.85 Million |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |